Avexitide
As of the edition of 20 October 2026, Avexitide is a protein: stopped in 2024; acts on GLP1R.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2024
- Kind
- Protein
- Registered trials
- 36, 4 stopped early
- Disease areas
- Nutrition and metabolism; Hormones; Digestive system; Inherited and neonatal; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Avexitide.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| GLP1R | Glucagon-like peptide 1 receptor | P43220 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 11 | 7 | 1 | 0 |
| Phase 1 | 11 | 6 | 4 | 1 |
| Phase 2 | 8 | 6 | 0 | 2 |
| Phase 3 | 2 | 1 | 1 | 0 |
| Phase 4 | 4 | 3 | 0 | 1 |
| All trials | 36 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Eiger BioPharmaceuticals | Lead sponsor of trials | 2018 to now |
| Amylyx Pharmaceuticals | Lead sponsor of trials |